A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Lawitz, Eric J; Gruener, Daniel; Hill, John M; Marbury, Thomas; Moorehead, Lisa; Mathias, Anita; Cheng, Guofeng; Link, John O; Wong, Kelly A; Mo, Hongmei; McHutchison, John G; Brainard, Diana M

Lawitz, Eric J; Gruener, Daniel; Hill, John M; Marbury, Thomas; Moorehead, Lisa; Mathias, Anita; Cheng, Guofeng; Link, John O; Wong, Kelly A; Mo, Hongmei; McHutchison, John G; Brainard, Diana M.

Affiliation

Lawitz EJ; Alamo Medical Research, San Antonio, TX, USA. lawitz@alamomedicalresearch.com

J Hepatol ; 57(1): 24-31, 2012 Jul.

Article in En | MEDLINE | ID: mdl-22314425

Subject(s)

Antiviral Agents/administration & dosage; Benzimidazoles/administration & dosage; Fluorenes/administration & dosage; Hepacivirus/drug effects; Hepatitis C, Chronic/drug therapy; Viral Nonstructural Proteins/antagonists & inhibitors; Adolescent; Adult; Aged; Antiviral Agents/adverse effects; Antiviral Agents/pharmacokinetics; Benzimidazoles/adverse effects; Benzimidazoles/pharmacokinetics; Dose-Response Relationship, Drug; Drug Resistance, Viral/genetics; Female; Fluorenes/adverse effects; Fluorenes/pharmacokinetics; Genotype; Hepacivirus/genetics; Humans; Male; Middle Aged; Placebos; RNA, Viral/metabolism; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Benzimidazoles / Viral Nonstructural Proteins / Hepacivirus / Hepatitis C, Chronic / Fluorenes Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google